Skip to navigation Skip to content



New data published from Canadian CCSVI prevalence study

October 8, 2013

Results from a Canadian research study investigating the prevalence of CCSVI in MS and others was published early online on October 8, 2013 in the medical journal The Lancet. The team led by Dr. Anthony Traboulsee, University of British Columbia, with Dr. Katherine Knox, director of the Saskatoon MS clinic, was among seven teams supported by a joint initiative by the National MS Society and the MS Society of Canada.

Read details about this study on the MS Society of Canada’s Website.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.